Eff ect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

Avezum, A; Piegas, L; Bertolami, M; Borges, J; Faludi, A

Eff ect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial / Eff ect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

Avezum, A; Piegas, L; Bertolami, M; Borges, J; Faludi, A.

Afiliación

Avezum, A; Instituto Dante Pazzanese de Cardiologia. BR
Piegas, L; Instituto Dante Pazzanese de Cardiologia. BR
Bertolami, M; Instituto Dante Pazzanese de Cardiologia. BR
Borges, J; Instituto Dante Pazzanese de Cardiologia. BR
Faludi, A; Instituto Dante Pazzanese de Cardiologia. BR

Lancet ; 368(9541): 1096-1105, 23 sep 2006.

Article en Pt | SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1064567

Biblioteca responsable: BR79.1

Ubicación: BR79.1

ABSTRACT

ABSTRACT

Background Rosiglitazone is a thiazolidinedione that reduces insulin resistance and might preserve insulin secretion.

Asunto(s)

Humanos; Diabetes Mellitus; Glucosa

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

Colección: 06-national / BR Base de datos: SES-SP / SESSP-IDPCPROD Asunto principal: Diabetes Mellitus / Glucosa Tipo de estudio: Clinical_trials Límite: Humans Idioma: Pt Revista: Lancet Año: 2006 Tipo del documento: Article

Buscar en Google

Añadir a Mi BVS

Imprimir

XML